Quantity of IgG response to SARS-CoV-2 spike glycoprotein predicts pulmonary recovery from COVID-19
-
Published:2022-03-07
Issue:1
Volume:12
Page:
-
ISSN:2045-2322
-
Container-title:Scientific Reports
-
language:en
-
Short-container-title:Sci Rep
Author:
Nairz Manfred, Sahanic Sabina, Pizzini Alex, Böhm Anna, Tymoszuk Piotr, Mitterstiller Anna-Maria, von Raffay Laura, Grubwieser Philipp, Bellmann-Weiler Rosa, Koppelstätter Sabine, Schroll Andrea, Haschka David, Zimmermann Martina, Blunder Silvia, Trattnig Kristina, Naschberger Helene, Klotz WernerORCID, Theurl Igor, Petzer Verena, Gehrer Clemens, Mindur John E., Luger Anna, Schwabl Christoph, Widmann Gerlig, Weiss GünterORCID, Löffler-Ragg Judith, Tancevski Ivan, Sonnweber Thomas
Abstract
AbstractThe CovILD study is a prospective, multicenter, observational cohort study to systematically follow up patients after coronavirus disease-2019 (COVID-19). We extensively evaluated 145 COVID-19 patients at 3 follow-up visits scheduled for 60, 100, and 180 days after initial confirmed diagnosis based on typical symptoms and a positive reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We employed comprehensive pulmonary function and laboratory tests, including serum concentrations of IgG against the viral spike (S) glycoprotein, and compared the results to clinical data and chest computed tomography (CT). We found that at the 60 day follow-up, 131 of 145 (90.3%) participants displayed S-specific serum IgG levels above the cut-off threshold. Notably, the highly elevated IgG levels against S glycoprotein positively correlated with biomarkers of immune activation and negatively correlated with pulmonary function and the extent of pulmonary CT abnormalities. Based on the association between serum S glycoprotein-specific IgG and clinical outcome, we generated an S-specific IgG-based recovery score that, when applied in the early convalescent phase, accurately predicted delayed pulmonary recovery after COVID-19. Therefore, we propose that S-specific IgG levels serve as a useful immunological surrogate marker for identifying at-risk individuals with persistent pulmonary injury who may require intensive follow-up care after COVID-19.
Funder
Austrian Science Fund Land Tirol Forschungsförderung, Project GZ 71934 Boehringer Ingelheim
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Reference69 articles.
1. Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 324, 782–793. https://doi.org/10.1001/jama.2020.12839 (2020). 2. Streeck, H. et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nat. Commun. 11, 5829. https://doi.org/10.1038/s41467-020-19509-y (2020). 3. Buitrago-Garcia, D. et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 17, e1003346. https://doi.org/10.1371/journal.pmed.1003346 (2020). 4. Tay, M. Z., Poh, C. M., Renia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363–374. https://doi.org/10.1038/s41577-020-0311-8 (2020). 5. Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B. & Wu, J. C. COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 17, 543–558. https://doi.org/10.1038/s41569-020-0413-9 (2020).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|